Financial Performance - The group's revenue for the year ended December 31, 2022, was approximately RMB 2,364.5 million, an increase of 28.6% compared to RMB 1,838.8 million for the year ended December 31, 2021[2]. - The group's net profit for the year ended December 31, 2022, was approximately RMB 117.9 million, a decrease of 66.7% from RMB 353.7 million for the year ended December 31, 2021[2]. - The adjusted net profit under non-IFRS was approximately RMB 274.1 million, down 39.8% from RMB 455.3 million for the previous year[2]. - The non-IFRS EBITDA for the year ended December 31, 2022, was approximately RMB 367 million, a decrease of 33.1% from RMB 548.5 million for the year ended December 31, 2021[2]. - The adjusted non-IFRS EBITDA was approximately RMB 479.1 million, down 23% from RMB 622.5 million for the previous year[2]. - Basic earnings per share for the year ended December 31, 2022, were RMB 0.05, compared to RMB 0.14 for the previous year[8]. - The board did not recommend a final dividend for the year ended December 31, 2022, compared to a dividend of HKD 0.0738 per share for the previous year[2]. - The total comprehensive income for the year ended December 31, 2022, was RMB 447.6 million, compared to RMB 196.9 million for the previous year[8]. Assets and Liabilities - Non-current assets increased to RMB 13,328,163 thousand in 2022 from RMB 10,282,258 thousand in 2021, representing a growth of approximately 29.9%[9]. - Current liabilities rose significantly to RMB 2,763,971 thousand in 2022, compared to RMB 1,071,522 thousand in 2021, marking an increase of about 157.5%[10]. - The company's total assets minus current liabilities amounted to RMB 12,468,066 thousand in 2022, up from RMB 11,753,868 thousand in 2021, indicating a growth of approximately 6.1%[10]. - The net asset value stood at RMB 8,735,128 thousand in 2022, slightly down from RMB 8,752,701 thousand in 2021, reflecting a decrease of about 0.2%[10]. - The company reported a significant increase in accounts payable and other payables, which reached RMB 916,929 thousand in 2022, compared to RMB 445,518 thousand in 2021, an increase of approximately 106.5%[10]. - The goodwill increased to RMB 3,484,725 thousand in 2022 from RMB 2,719,747 thousand in 2021, representing a growth of about 28.1%[9]. - Deferred tax assets rose to RMB 88,516 thousand in 2022, compared to RMB 7,020 thousand in 2021, indicating a substantial increase of approximately 1,125.4%[9]. - The company’s cash and cash equivalents increased to RMB 1,316,549 thousand in 2022 from RMB 862,325 thousand in 2021, reflecting a growth of approximately 52.7%[9]. Operational Highlights - The company continues to focus on expanding its assisted reproductive services and related healthcare offerings, aiming for further market penetration and growth in the coming years[11]. - The group's revenue for the year ended December 31, 2022, primarily came from operations in Chengdu, Shenzhen, Wuhan, Kunming, the United States, and Hong Kong[20]. - The acquisition of a new business in Kunming was completed during the year ended December 31, 2022[20]. - The group reported its operating segments based on geographical areas, specifically Greater China and the United States[20]. - The company reported a pre-tax profit of RMB 154,324 thousand for the current year, compared to RMB 457,927 thousand in the previous year[21][22]. - The company recorded a loss of RMB 34,543 thousand from the sale of property, plant, and equipment[25]. - The company’s administrative expenses included share-based compensation of RMB 87,437 thousand[21]. - The company reported a fair value change loss of RMB 76,733 thousand on preferred stock investments[21]. Research and Development - Research and development expenses for the year were RMB 17.5 million, an increase from RMB 10.7 million in the previous year[6]. - The company has increased investment in R&D to enhance clinical transformation and improve clinical standards[59]. - The company published a total of 106 scientific papers in 2022, including 38 in core journals, and obtained 35 scientific research projects[79]. - The company established the Jinxin Medical Innovation Research Center in January 2022 to enhance research management and clinical application[79]. Market Expansion and Strategy - The company aims to leverage the growth potential in the Greater Bay Area, aligning with national strategies to enhance market share[74]. - The company is actively seeking acquisition opportunities in Southeast Asia, believing in significant growth potential in the assisted reproduction sector[78]. - The company plans to continue its expansion in the Chinese market, leveraging its established network of hospitals and clinics[141]. - The company aims to strengthen clinical research and its transformation into clinical applications to enhance competitiveness and create new business growth points[79]. Governance and Compliance - The group has maintained compliance with all applicable corporate governance codes throughout the year ended December 31, 2022[123]. - The company is focused on enhancing its governance and risk management practices as part of its corporate governance code compliance[139]. Employee and Operational Metrics - As of December 31, 2022, the group employed a total of 3,158 employees, with 2,761 in China and 397 in the United States[120]. - Employee costs for the year ended December 31, 2022, amounted to approximately RMB 674.9 million, compared to RMB 457.9 million for the year ended December 31, 2021, representing a year-over-year increase of 47.5%[120]. - The company provided training courses in assisted reproductive technology to 1,378 clinical staff during the year ended December 31, 2022[80]. Future Outlook - The company aims to expand its service range to provide comprehensive fertility services covering pre-pregnancy, IVF, prenatal, delivery, and postnatal care[76]. - The company plans to renovate Jiuzhou Hospital in the first half of 2023 to optimize service environment and expand capacity[75].
锦欣生殖(01951) - 2022 - 年度业绩